BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30243902)

  • 1. The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer.
    Zhang W; Feng H; Chen Q; Lu X; Ge J
    Exp Cell Res; 2018 Nov; 372(2):92-98. PubMed ID: 30243902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Killer Cells Induce CD8
    Liu S; Xu C; Yang F; Zong L; Qin Y; Gao Y; Su Q; Li T; Li Y; Xu Y; Zheng M
    Front Immunol; 2022; 13():884290. PubMed ID: 35874664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tim-3 Is Upregulated in NK Cells during Early Pregnancy and Inhibits NK Cytotoxicity toward Trophoblast in Galectin-9 Dependent Pathway.
    Sun J; Yang M; Ban Y; Gao W; Song B; Wang Y; Zhang Y; Shao Q; Kong B; Qu X
    PLoS One; 2016; 11(1):e0147186. PubMed ID: 26789128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal-fetal interface in early pregnancy.
    Li YH; Zhou WH; Tao Y; Wang SC; Jiang YL; Zhang D; Piao HL; Fu Q; Li DJ; Du MR
    Cell Mol Immunol; 2016 Jan; 13(1):73-81. PubMed ID: 25578313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer.
    Yin M; Di G; Bian M
    Int Immunopharmacol; 2018 Nov; 64():333-339. PubMed ID: 30243069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-9 functionally impairs natural killer cells in humans and mice.
    Golden-Mason L; McMahan RH; Strong M; Reisdorph R; Mahaffey S; Palmer BE; Cheng L; Kulesza C; Hirashima M; Niki T; Rosen HR
    J Virol; 2013 May; 87(9):4835-45. PubMed ID: 23408620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cell expression of Tim-3: First impressions matter.
    So EC; Khaladj-Ghom A; Ji Y; Amin J; Song Y; Burch E; Zhou H; Sun H; Chen S; Bentzen S; Hertzano R; Zhang X; Strome SE
    Immunobiology; 2019 May; 224(3):362-370. PubMed ID: 30876792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection.
    Jost S; Moreno-Nieves UY; Garcia-Beltran WF; Rands K; Reardon J; Toth I; Piechocka-Trocha A; Altfeld M; Addo MM
    Retrovirology; 2013 Jul; 10():74. PubMed ID: 23866914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway.
    Mujib S; Jones RB; Lo C; Aidarus N; Clayton K; Sakhdari A; Benko E; Kovacs C; Ostrowski MA
    J Immunol; 2012 Apr; 188(8):3745-56. PubMed ID: 22422881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells.
    Choi YH; Lim EJ; Kim SW; Moon YW; Park KS; An HJ
    J Immunother Cancer; 2019 Jul; 7(1):168. PubMed ID: 31277710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss.
    Li Y; Zhang J; Zhang D; Hong X; Tao Y; Wang S; Xu Y; Piao H; Yin W; Yu M; Zhang Y; Fu Q; Li D; Chang X; Du M
    Sci Signal; 2017 Sep; 10(498):. PubMed ID: 28951537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-21-mediated expansion of Vγ9Vδ2 T cells is limited by the Tim-3 pathway.
    Wu K; Zhao H; Xiu Y; Li Z; Zhao J; Xie S; Zeng H; Zhang H; Yu L; Xu B
    Int Immunopharmacol; 2019 Apr; 69():136-142. PubMed ID: 30708194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.
    Sahm C; Schönfeld K; Wels WS
    Cancer Immunol Immunother; 2012 Sep; 61(9):1451-61. PubMed ID: 22310931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-21 reinvigorates exhausted natural killer cells in patients with HBV-associated hepatocellular carcinoma in STAT1-depedent pathway.
    Jin Y; Sun Z; Geng J; Yang L; Song Z; Song H; Wang J; Tang J
    Int Immunopharmacol; 2019 May; 70():1-8. PubMed ID: 30780004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
    Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
    J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy: TIM-3/galectin-9 interaction and its possible role during pregnancy.
    Meggyes M; Miko E; Polgar B; Bogar B; Farkas B; Illes Z; Szereday L
    PLoS One; 2014; 9(3):e92371. PubMed ID: 24651720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours.
    Seo H; Jeon I; Kim BS; Park M; Bae EA; Song B; Koh CH; Shin KS; Kim IK; Choi K; Oh T; Min J; Min BS; Han YD; Kang SJ; Shin SJ; Chung Y; Kang CY
    Nat Commun; 2017 Jun; 8():15776. PubMed ID: 28585539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tim-3 pathway affects NK cell impairment in patients with active tuberculosis.
    Wang F; Hou H; Wu S; Tang Q; Huang M; Yin B; Huang J; Liu W; Mao L; Lu Y; Sun Z
    Cytokine; 2015 Dec; 76(2):270-279. PubMed ID: 26050547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
    Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.